Investment firm Kahn Brothers (Trades, Portfolio) Group was founded by 1978 by Irving Kahn, Thomas Graham Kahn and Alan Kahn. The firm sold shares of the following stocks in the second quarter.
The firm trimmed 20.40% off its New York Times Co. (NYT) holding, impacting the portfolio by -1.77%.
The publishing company, which prints the renowned New York Times newspaper, has a market cap of $4.01 billion and an enterprise value of $3.74 billion.
GuruFocus gives the company a profitability and growth rating of 5 out of 10. The return on equity of 1.44% and return on assets of 0.60% are underperforming 67% of companies in the Global Publishing industry. Its financial strength is rated 7 out of 10. The cash-debt ratio of 2.05 is above the industry median of 1.36.
The firm is the largest shareholder of the company among the gurus with 1.25% of outstanding shares, followed by Jim Simons (Trades, Portfolio)' Renaissance Technologies with 0.7% and Barrow, Hanley, Mewhinney & Strauss with 0.25%.
The Hologic Inc. (HOLX) position was reduced by 7.14%. The trade had an impact of -0.28% on the portfolio.
The manufacturer of diagnostic and surgical products has a market cap of $11.33 billion and an enterprise value of $14.02 billion.
GuruFocus gives the company a profitability and growth rating of 7 out of 10. The return on equity of -2.88% and return on assets of -1.03% are outperforming 87% of companies in the Global Medical Instruments and Supplies industry. Its financial strength is rated 5 out of 10. The cash-debt ratio of 0.18 is below the industry median of 1.74.
The largest guru shareholder of the company is the Vanguard Health Care Fund (Trades, Portfolio) with 1.81% of outstanding shares, followed by Pioneer Investments (Trades, Portfolio) with 0.56% and Jerome Dodson (Trades, Portfolio) with 0.3%.
The BP PLC (BP) stake was curbed by 1.14%. The transaction had an impact of -0.1% on the portfolio.
The oil and gas giant has a market cap of $146.74 billion and an enterprise value of $186.22 billion.
GuruFocus gives the company a profitability and growth rating of 4 out of 10. The return on equity of 7.06% and return on assets of 2.56% are underperforming 69% of companies in the Global Oil and Gas Integrated industry. Its financial strength is rated 6 out of 10. The cash-debt ratio of 0.37 is above the industry median of 0.34.
Barrow, Hanley, Mewhinney & Strauss is the company's largest shareholder among the gurus with 0.98% of outstanding shares, followed by Simons' firm with 0.22% and Richard Pzena (Trades, Portfolio) with 0.16%.
Kahn Brothers cut 0.95% off its Citigroup Inc. (C) position, impacting the portfolio by -0.1%.
The bankk has a market cap of $181.35 billion and an enterprise value of $274.41 billion.
GuruFocus gives the company a profitability and growth rating of 3 out of 10. The return on equity of -3.24% and return on assets of -0.3% are underperforming 95% of companies in the Global Banks - Global industry. Its financial strength is rated 4 out of 10. The cash-debt ratio of 0.73 is below the industry median of 2.12.
With 0.64% of outstanding shares, Jeff Ubben (Trades, Portfolio)'s ValueAct is the company's largest guru shareholder, followed by Barrow, Hanley, Mewhinney & Strauss with 0.56%, Hotchkis & Wiley with 0.41% and Diamond Hill Capital (Trades, Portfolio) with 0.37%.
The firm's Sterling Bancorp (STL) holding was reduced by 2.41%. The trade had an impact of -0.08% on the portfolio.
The financial services company has a market cap of $4.99 billion and an enterprise value of $10.21 billion.
GuruFocus gives the company a profitability and growth rating of 4 out of 10. The return on equity of 6.52% and return on assets of 0.90% are underperforming 81% of companies in the Global Banks - Regional - U.S. industry. Its financial strength is rated 4 out of 10. The cash-debt ratio of 0.08 is below the industry median of 2.12.
Of the gurus invested in the company, Diamond Hill has the largest position with 0.95% of outstanding shares, followed by Mario Gabelli (Trades, Portfolio) with 0.51%.
The Merck & Co. Inc. (MRK) holding was trimmed by 0.81%, impacting the portfolio by -0.06%.
The health care company has a market cap of $179.12 billion and an enterprise value of $195.56 billion.
GuruFocus gives the company a profitability and growth rating of 5 out of 10. The return on equity of 3.61% and return on assets of 1.47% are underperforming 54% of the companies in the Global Drug Manufacturers - Major industry. Its financial strength is rated 6 out of 10. The cash-debt ratio of 0.39 is below the industry median of 0.64.
The company's largest guru shareholder is the Vanguard Health Care Fund with 0.86% of outstanding shares, followed by Dodge & Cox with 0.51%, Barrow, Hanley, Mewhinney & Strauss with 0.47% and Ken Fisher (Trades, Portfolio) with 0.29%.
Disclosure: I do not own any stocks mentioned in this article.
